close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Niagen Bioscience, Inc

< Previous 1 2 Next >
News headline image
Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience Announces $10 Million Share Repurchase Program
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience to Present at Canaccord Genuity’s 45th Annual Growth Conference
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience to Participate at the Roth 15th Annual London Conference
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience to Participate in the BIO 2025 International Convention
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience to Present at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
News headline image
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms
From Niagen Bioscience, Inc
Via Business Wire
Tickers NAGE
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.